Hypercholesterolemia Clinical Trial
Official title:
Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols In Chilean Subjects With Hypercholesterolemia
Hypercholesterolemia is an important risk factor for cardiovascular disease, asociated
primarily with high plasma levels of LDL lipoprotein, which in turn depend on the endogenous
hepatic synthesis of cholesterol and its absorption at intestinal level. It has been
demonstrated that there reducing plasma LDL is beneficial, mainly with the use of statins,
which are the first treatment option for a moderate hypercholesterolemia.
Phytosterols reduce the intestinal absorption of cholesterol by reducing its incorporation
into lipid micelles. Consequently, phytosterols have become a relevant alternative treatment
against low hypercholesterolemia. The target population are 40 to 65 years old individuals
with low hypercholesterolemia.
Different protocols have demonstrated that phytosterol intake fluctuates between 1000 to
2000 mg per day decreasing LDL by around 10%, independently of levels of blood triglycerides
and HDL (high density lipoproteins) concentrations. In fact, the National Cholesterol
Education Program and the American Heart Association recommend the addition of 2 g/day of
phytosterols to daily diet of adults. This is also recommended by the FDA (Food and Drug
administration).
Phytosterols delivery has been proven effective when administrated in lipid matrixes such as
margarines and dressings and low-fat such as skimmed milk and yogurt, proving to have an
hypolipidemic effect. The investigational products consist of powder milk and a drinking
yoghurt with the addition of esterified phytosterols, with a total daily intake of 1.95
g/day (1.17 g/day of free equivalent).
Primary objective: To evaluate the impact in Chilean population of phytosterols incorporated
into dairy products in reduction of LDL cholesterol.
Secondary objectives:
1. To evaluate potential changes in blood cholesterol concentration according to
nutritional state and age.
2. To determine the appearance of symptoms and/or effects during the intervention period.
The trial has been designed to evaluate the effect of phytosterols incorporated to low fat
dairy products in Chile, through the consumption of one glass of milk powder and 90 mL of
drinking yoghurt, which results in a daily consumption of 1.95 g/day of esterified
phytosterols. This amount falls within demonstrated effective doses reported in literature.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Recruiting |
NCT03947866 -
Ezetimibe-Rosuvastatin Evaluation Study
|
||
Completed |
NCT01709513 -
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
|
Phase 3 | |
Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
Completed |
NCT02550288 -
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
|
Phase 3 | |
Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
Completed |
NCT04485793 -
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
|
N/A | |
Completed |
NCT02341924 -
Validating the "Foods for Health" Portfolio of Functional Food Products
|
N/A | |
Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
Completed |
NCT01941836 -
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
|
Phase 2 | |
Completed |
NCT01934608 -
The Effect of Synching Prescription Refills on Adherence
|
N/A | |
Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
Completed |
NCT01678521 -
Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients
|
N/A | |
Completed |
NCT01670734 -
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01370590 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
|
Phase 3 | |
Completed |
NCT01370603 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
|
Phase 3 | |
Completed |
NCT01575171 -
Using Nudges to Implement Comparative Effectiveness
|
N/A | |
Completed |
NCT01768403 -
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
|
N/A | |
Completed |
NCT01446679 -
Special Drug Use-Results Survey of Lipitor Tablets
|
N/A |